Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SNFCA traded a 60k and a 30k block at 10.54 in the final minutes...
https://quotes.freerealtime.com/quotes/SNFCA/Time%26Sales
...someone else likes it.
SNFCA 10.54 - very strong close in the final minutes. Both price & volume. Don't see any news...
ENHT .004 / .0055 - is an old crusty stinkypinky shell that's been dormant for years. Trading at a $50K cap if the numbers are still correct...
AATV reports quarterly as a pinksheet...
https://www.otcmarkets.com/stock/AATV/disclosure
The "streaming tv" sector is on fire and these guys seem to have been involved in it for more than 15 years.
AATV .48 - Jun 05, 2007...J. Michael Heil, C.E.O. of Synergetic Technologies, said, "Ad systems can now insert ads on over fifty cable networks with another 25 networks scheduled for third quarter. Our goal is to have the ability to insert ads on every major cable network and to make our systems accessible by all advertisers. With over 70,000 homes installed we have begun building a truly global advertising media previously untapped by advertisers."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=20464924
How likely is it that J. Michael Heil has been pulling-our-legs for more than 15 years? My crystal ball shows otherwise...
AATV (ask) .495 - adding/plunging while someone continues giving shares away? Is anyone joining me in this venture or am I flying solo here while we await Q4 results anyday now?
Q3 - Revenue $3.5M / EPS .035
Q4 - Revenue $5.7M / EPS ???
Revenue recorded for the fourth quarter of 2020 exceeded $5.71 million, for an increase of more than double from that prior largest quarter.
https://www.otcmarkets.com/stock/AATV/news/Adaptive-Ad-Systems-Announces-Record-Revenue-For-4th-Quarter-2020-Exceeding-571-Million?id=289072
I've sidelined all shorting-strategies while trying to maintain a large cash position in search of the more lucrative, much less risky, and in my value-analysis-wheelhouse dip-buying oppurtunities.
I just can't figure out how to make any "sizeable" gain with any short strategy - all high-risk / low-reward imo? Using SFIX as an example...
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=sfix&insttype=&freq=1&show=&time=7
...this flyingpig finally got some deserved come-uppins but where would one have started shorting and how would one have obtained any "sizeable" gain?
"...The Company plans to begin trials by the end of Q2 2020..."
https://www.otcmarkets.com/stock/NBIO/profile
Still not updated!!! Seriously Clark?
Sold a ton at .09's - .08's trimming back to a more comfortable flipping position as we await this CEO (or a NEW CEO perhaps)...one that's willing to exhibit even an iota of enthusiasm?
VBIV 3.35 - receives grant from CEPI:
On March 9, 2021, Variation Biotechnologies Inc., a Canadian federal corporation and a wholly-owned subsidiary of VBI Vaccines Inc. (together with Variation Biotechnologies Inc., the “Company”) and the Coalition for Epidemic Preparedness Innovations (the “CEPI”) entered into a funding agreement (the “Agreement”), pursuant to which CEPI will provide up to $33 million to support the advancement of the Company’s enveloped virus like particle (“eVLP”) vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant first identified in South Africa. The Company is to use commercially reasonable efforts to undertake the development of such vaccine candidates.
https://ih.advfn.com/stock-market/NASDAQ/vbi-vaccines-VBIV/stock-news/84542798/current-report-filing-8-k
Doubled down in premarket and anticipating some extreme covered-call opps this morning on this news...
VBIV 3.35 - receives grant from CEPI:
On March 9, 2021, Variation Biotechnologies Inc., a Canadian federal corporation and a wholly-owned subsidiary of VBI Vaccines Inc. (together with Variation Biotechnologies Inc., the “Company”) and the Coalition for Epidemic Preparedness Innovations (the “CEPI”) entered into a funding agreement (the “Agreement”), pursuant to which CEPI will provide up to $33 million to support the advancement of the Company’s enveloped virus like particle (“eVLP”) vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant first identified in South Africa. The Company is to use commercially reasonable efforts to undertake the development of such vaccine candidates.
https://ih.advfn.com/stock-market/NASDAQ/vbi-vaccines-VBIV/stock-news/84542798/current-report-filing-8-k
You mean a 'special-purpose-acquisition-company' might possibly fail in their special-purpose-acquisition??? Who knew...
RIGL 4.06 - filed 10K yesterday afterclose and got totally ignored. This one has multiple HOT HOT HOT irons in the fire and getting zero respect for the LLY upfront payment of $125M...ie - they'll have no nearterm need for financing (printing new shares) and in the Q1 report upcoming very soon, we can look forward to showing a whopping profit...
https://www.marketwatch.com/press-release/rigel-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-business-update-2021-03-02?siteid=bigcharts&dist=bigcharts&tesla=y
...really like this one for longterm and with any pop in pps, the option premiums could once again become lucrative
Covered call premiums are especially high on my 'bread-n-butter' cashfat-biobusts. Having the time of my life with all trading per se mostly moved to the backburner...
See CLBS, HEPA, TRVN, TYME...
the new trading - "rolling" weekly or monthly covered calls
OCGN 12.20 - also added. Covered call premiums at 20%+ for 2-1/2 weeks (March 19 expiration). You gotta love these robinhooligans, no?
VXRT - February 25, 2021, 3:01 PM...VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021
https://finance.yahoo.com/news/vaxart-provides-business-reports-fourth-210100371.html
Long term story here is just fine...
The data show that Pritumumab ("PTB") successfully blocked 80% of viral entry into cells. Based on these results, PTB will be advanced to laboratory-based animal studies.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Announces-Successful-Pritumumab-In-Vitro-Trial-Data-in-Collaborative-Covid-19-Treatment-Study-with-Syrac?id=290256
It's the short-term rinkydinkystinkypinky way NBIO management treats we retail shareholders with information, lack of information.
In layman-speak: If it trades rinkydinkystinkypinky then trade it like it's a rinkydinkystinkypinky
Long term story here is just fine...
The data show that Pritumumab ("PTB") successfully blocked 80% of viral entry into cells. Based on these results, PTB will be advanced to laboratory-based animal studies.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Announces-Successful-Pritumumab-In-Vitro-Trial-Data-in-Collaborative-Covid-19-Treatment-Study-with-Syrac?id=290256
It's the short-term rinkydinkystinkypinky way NBIO management treats we retail shareholders with information, lack of information.
In layman-speak: If it trades rinkydinkystinkypinky then trade it like it's a rinkydinkystinkypinky
"scheduled to begin in February, 2021"...surely we outsider-shareholders will receive an update either today or tomorrow???
Otherwise...rinkydinky is as rinkydinky does
providing evidentiary links in support of verbage will sometimes induce "chatter", no?
CLBS 1.88 - bought a ton more this morning and sold the March-$2-calls at .25 and .30. They also recently sold a bunch in secondary at $2.
Joined you in some high-premium-OCGN, thanks. Will this 'high-premiums' party ever end...?
This will take us through Phase I/II clinical trials which are scheduled to begin in February, 2021.
I'm laying the current odds at 50/50 they whiff on this...
CPSS 4.39 - Q4 scheduled for Wednesday, 2/24. Yahoofinance estimate "68M REV / .23 EPS"...
https://finance.yahoo.com/quote/CPSS/analysis?p=CPSS
Snagged a few to hold into earnings on current solid BV and EPS. Anyone else buying or selling?
Ohhh myyy...fed taxes on stocktrades???...you are a visionary
and there's an absolute #1 in the scope of under .10 (well, not under .10 anymore) pennystocks...
...with a Phase-1 Cancer trial on the very near horizon...
Dew - do you know which pennystock?
AATV .64 - I'm no expert on what AATV does - from AATV pr:
ABOUT ADAPTIVE
Adaptive Ad Systems Inc. is a digital media and video communications company that together with its subsidiary manufactures, develops and deploys dynamic digital ad insertion (DDAI) and video streaming media hardware and proprietary processing software for the Cable TV, Satellite TV, and IPTV markets. Adaptive's primary focus is the 2nd and 3rd tier US markets. Adaptive exclusively sells all available advertising space in each market across multiple national cable television networks, while maintaining complete technology ownership. Adaptive has implemented a unique profit-sharing model with its cable TV partners. The Company serves over 200 designated marketing areas in approximately 39 states. Adaptive also provides broadband and cable TV services in some niche markets. For additional information, please visit: www.adaptiveadsystems.com.
IPTV market: https://www.mordorintelligence.com/industry-reports/internet-protocol-television-iptv-market
RIGL 5.60 - follows an award from BARDA with a sizeable Eli Lilly contract...
Under the terms of the License Agreement, Rigel receives an upfront cash payment of $125 million
https://ih.advfn.com/stock-market/NASDAQ/rigel-pharmaceuticals-RIGL/stock-news/84371689/current-report-filing-8-k
In very tall standing (arguably #1) in the scope of $5 biotech's!
RIGL 5.60 - follows an award from BARDA with a sizeable Eli Lilly contract...
Under the terms of the License Agreement, Rigel receives an upfront cash payment of $125 million
https://ih.advfn.com/stock-market/NASDAQ/rigel-pharmaceuticals-RIGL/stock-news/84371689/current-report-filing-8-k
In very tall standing (arguably #1) in the scope of $5 biotech's!
NBIO .119 - In a research collaboration with Nascent Biotech, who are developing human anti-vimentin antibodies for clinical cancer studies, the team reports positive results, demonstrating that the same antibodies against vimentin can block up to 80% of host cell invasion. Their results suggest a new target and therapeutic strategy to reduce SARS-CoV-2 attachment and entry into the cell, which could reduce the spread of SARS2.
https://thecollege.syr.edu/news-all/news-from-2021/keeping-sars2-out-of-the-cell/
...and commencement of NBIO's Phase-1-Cancer-Trial has yet to be formally announced...
The news we were looking for and the onset of the Phase-1 Cancer-Trial at the Hoag Clinic news should be coming by next week...
TNXP is one of the worst abusers of a public printing press...about as sleazy as you'll find of any listed biotech imo.
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=tnxp&insttype=&freq=2&show=&time=20
Exactly!
SNDL 2.50 - have a triple-down bid at 1.85. As long as the options premiums remain sky-high (20% for less than 2 days), it will continue to be like taking candy from babies...
...and not if, but when, this ludicrous option premiums phenomenom peters out, I'm planning on (joining wade) taking a long vacation from trading...
SNDL 2.85 - just bought here and then sold the $4-Feb.12-Calls at .60!
That's 21% juice for a day-and-a-half plus I could get lucky for another potential $1.15 gain in a day-and-a-half!
Viva la robinhooligans
AATV .41 - added here yesterday as someone continues selling...while this company just announced a record $5.71M-Revenue 4th quarter to follow the 3rd quarter:
$3.5M Revenue / $.035 EPS
https://backend.otcmarkets.com/otcapi/company/financial-report/264377/content
At the otcmarkets.com 'company profile' page, it clearly states:
"The Company plans to begin trials by the end of Q2 2020."
https://www.otcmarkets.com/stock/NBIO/profile
I sent an email to Sean Carrick weeks ago requesting he clean-that-chitt-up at likely the most sought out go-to-information-website for any new investor in pennystocks & no response other than this company's normal crickets
SNDL 2.98 - I looked at it when you posted and entered a bid at .85 when it was dipping into the .90's. Who knew it would skyrocket to $3 on 2B volume today??
Viva la robinhooligans...
NEED FOR ADDITIONAL FINANCING:
Our current capital needs are estimated to be approximately $17 million of which $2 million for phase I trials and $15 million for phase II trials. This will take us through Phase I/II clinical trials which are scheduled to begin in February, 2021.
https://www.otcmarkets.com/filing/html?id=14683713&guid=SXCKUHMf3hv_nth
Filed on the 9th of February, that leaves 19 days to get-er-done, surely they won't whiff this statement...but I'm beginning to question Sean Carrick's aptitude...the persistent ignoring-shareholder-silence is deafening!?
LUVU .126 - nice trading amigo. Can you make any case for an upside surprise earnings? I had it a few months back at .07's, completely miffed the run to .40's and have since lost interest.
AATV .65 - exciting news: ...Compared to the Company's remarkable fourth quarter of 2020, the Company's largest revenue for any fourth quarter throughout the Company's history was about $2.74 million in 2018. Revenue recorded for the fourth quarter of 2020 exceeded $5.71 million, for an increase of more than double from that prior largest quarter...
https://www.otcmarkets.com/stock/AATV/news/Adaptive-Ad-Systems-Announces-Record-Revenue-For-4th-Quarter-2020-Exceeding-571-Million?id=289072
Donde esta las robinhooligans?